Outpatient therapeutic nuclear oncology

Area of Science:

• Oncology
• Nuclear Medicine
• Medical Imaging

Background:

• Nuclear medicine has evolved from radionuclide therapy to molecular tumor-targeted control of metastatic cancer.
• Accurate personalized dosimetry via quantitative gamma SPECT/CT imaging is crucial for safe and effective therapeutic nuclear oncology.
• Radionuclide selection balances therapeutic efficacy with imaging capability for dosimetry, minimizing radiation risks.

Purpose of the Study:

• To review the safety of outpatient radiopharmaceutical cancer therapy.
• To assess the feasibility of personalized dosimetry for tumoricidal activity without critical organ toxicity.
• To evaluate radiation exposure risks associated with outpatient radionuclide therapy.

Main Methods:

• Review of safety data for outpatient radiopharmaceutical therapy using radionuclides like Iodine-131, Samarium-153, Holmium-166, Rhenium-186, Rhenium-188, Lutetium-177, and Indium-111.
• Analysis of measured activity release rates and radiation exposure to carers and the public.
• Assessment of compliance with international regulatory agency guidelines.

Main Results:

• Outpatient radiopharmaceutical therapy for cancer is safe and cost-effective.
• Measured activity release rates and radiation exposure are within international guidelines.
• Personalized dosimetry enables tumoricidal activity without critical organ toxicity.

Conclusions:

• Therapeutic nuclear oncology can be safely practiced in outpatient settings.
• Quantitative SPECT/CT imaging allows for accurate dosimetry, enhancing treatment safety and efficacy.
• Outpatient radiopharmaceutical therapy offers a cost-effective and safe alternative to inpatient isolation for cancer treatment.